Retatrutide: A Step Beyond GLP-1 Therapy for the Future of Metabolic Health

The rise of GLP-1–based medications has forced a long-overdue shift in how we think about obesity. For decades, excess weight was framed as a simple failure of willpower. We now understand it as a complex, chronic, neuro-hormonal and metabolic condition, influenced by genetics, insulin resistance, inflammation, stress physiology, sleep, and environmental inputs.

Medications like Semaglutide and Tirzepatide have helped validate this perspective by demonstrating that when we address disrupted metabolic signaling, the body often responds in predictable and measurable ways.

Retatrutide is the next investigational medication in this evolving landscape — and while it is not yet FDA-approved, it represents a potentially meaningful advance in how metabolic dysfunction may be treated in the future.

What Is Retatrutide?

Retatrutide is an investigational, once-weekly injectable medication currently in Phase 3 clinical trials for obesity and metabolic disease. What makes it unique is its triple-agonist mechanism, meaning it activates three key hormone receptors involved in energy balance:

• GLP-1 (glucagon-like peptide-1)

• GIP (glucose-dependent insulinotropic polypeptide)

• Glucagon receptors

The GLP-1 medications that are currently available target only one or two of these pathways. Semaglutide activates GLP-1 alone. Tirzepatide activates GLP-1 and GIP. Retatrutide adds a third signal — glucagon — which may help explain its more robust effects on weight and metabolism!

From a functional medicine lens, this matters because obesity is not driven by a single broken pathway. It is the downstream expression of multiple signaling disruptions, particularly in insulin regulation, appetite control, satiety signaling, and energy expenditure.

Why Retatrutide May Be Superior to Current GLP-1 Medications

Traditional GLP-1 medications primarily reduce weight by decreasing caloric intake. They work by:

• Reducing appetite

• Increasing satiety

• Slowing gastric emptying

• Improving insulin secretion

These are meaningful effects, but they address only part of the metabolic picture.

Retatrutide appears to work on both sides of the energy balance equation:

• Eating less, through GLP-1 and GIP signaling

• Burning more, through glucagon receptor activation (meaning you're boosting your metabolism!!)

  
  

Glucagon signaling may increase fat oxidation and overall energy expenditure, which is particularly relevant in individuals with long-standing insulin resistance and metabolic adaptation from repeated dieting. This dual action may help explain why Retatrutide has produced greater average weight loss than earlier therapies in clinical trials.

Importantly, this does not mean Retatrutide is “stronger” in a simplistic sense — it is broader in its metabolic reach to maximize your results.

What Are the Phase 3 Trials Showing?

The most compelling data so far comes from Phase 2 trials and early Phase 3 readouts.

Across studies involving adults with obesity:

• Retatrutide has demonstrated average weight loss exceeding 25%, with some Phase 3 results approaching the high 25-30% range at the highest studied doses

• Weight loss has been dose-dependent, with greater reductions seen at higher doses

• Improvements have also been observed in cardiometabolic markers such as waist circumference, insulin resistance, and lipid profiles

• Patients with knee osteoarthritis have also shown improvements in pain

  
  

These outcomes exceed what has historically been seen with lifestyle intervention alone and are numerically greater than results from earlier GLP-1 medications.

Side effects reported in trials have been largely consistent:

• Nausea

• Vomiting

• Diarrhea

• Reduced appetite

  
  

Most adverse effects occurred during dose escalation and were mitigated by slow titration.

What Dose Appears to Produce the Maximum Effect?

In clinical trials, the highest studied dose of Retatrutide is 12 mg once weekly.

• This dose has consistently produced the greatest average weight loss

• Lower doses (such as 4 mg and 8 mg) were effective with 4mg being the "sweet spot" in being the lowest dose yet still seeing metabolic benefits from the drug

• Retatrutide is still investigational, there is no FDA-approved dosing recommendation yet, and final dosing will depend on Phase 3 outcomes and regulatory review.

  
  

When Might Retatrutide Be FDA Approved?

As of now, Retatrutide is not FDA-approved.

Based on current timelines:

• Phase 3 trials are expected to conclude in 2026

• A New Drug Application (NDA) may be submitted in late 2026

• FDA review typically takes 6–12 months

  
  

If data remain favorable, potential FDA approval could occur in 2027, with more conservative projections extending into late 2027 or early 2028. As with all investigational therapies, approval is not guaranteed and depends on safety, efficacy, and regulatory review.

What This Means for Functional Medicine and the Obesity Epidemic

From a functional medicine perspective, Retatrutide does not replace lifestyle, nutrition, movement, sleep, or nervous system regulation — but it may support the biology that allows those interventions to work more effectively.

For many patients with obesity:

• Metabolic dysfunction precedes weight gain

• Repeated caloric restriction worsens hormonal adaptation by spiking cortisol levels

• The body’s appetite signals and metabolism are out of sync, often pushing people to feel hungrier while burning fewer calories.

  
  

Medications like retatrutide may help restore metabolic signaling, giving patients a physiological foundation on which sustainable behavior change can occur.

This represents a shift away from viewing obesity as a personal failure and toward recognizing it as a treatable, chronic metabolic condition — a framing that aligns closely with functional medicine principles.

At the same time, these therapies raise important questions:

• How do we prevent muscle loss?

• How do we support micronutrient status?

• How do we address root contributors like insulin resistance, inflammation, stress, and sleep disruption?

  
  

These are areas where functional medicine remains essential. I’ll be sharing more information soon on how to preserve muscle mass and optimize nutritional intake while using these medications.

A Rooted in Wellness Takeaway

Retatrutide is one of the most promising investigational metabolic therapies to date, but it is still in development. While early data suggest it may outperform current GLP-1 medications in terms of weight loss, its long-term role will depend on safety, accessibility, and thoughtful integration into comprehensive care models.

For functional medicine practitioners and patients alike, Retatrutide is best viewed not as a cure-all, but as a potential future tool that acknowledges the biological reality of obesity and opens the door to more compassionate, effective metabolic care.

References:

Eli Lilly and Company. (2023). Lilly’s phase 2 retatrutide results published in The New England Journal of Medicine show the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity and overweight [Press release]. PR Newswire. https://www.prnewswire.com/news-releases/lillys-phase-2-retatrutide-results-published-new-england-journal-of-medicine-show-the-investigational-molecule-achieved-up-to-17-5-mean-weight-reduction-at-24-weeks-in-adults-with-obesity-and-overweight-301863690.html 

Lilly. (2025, December 11). Lilly’s triple agonist, retatrutide, delivered weight loss of up to an average 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial [News release]. Eli Lilly & Company Investor Relations. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average 

Retatrutide systematic review: authors not specified. (2024). Efficacy and safety of retatrutide, a novel GLP‑1, GIP, and glucagon receptor agonist for obesity treatment: A systematic review and meta‑analysis of randomized controlled trials. PubMed. https://pubmed.ncbi.nlm.nih.gov/40291085/ 

Retatrutide vs other agents: authors not specified. (2025). Efficacy and safety of GLP‑1 receptor agonists, dual agonists, and retatrutide for weight loss in adults with overweight or obesity: A Bayesian network meta‑analysis. PubMed. https://pubmed.ncbi.nlm.nih.gov/40685589/ 

Retatrutide clinical context (developer FAQ). (2025). What to know about retatrutide. Lilly.com. https://www.lilly.com/news/stories/what-to-know-about-retatrutide